50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today ACRS ranks #12614 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Aclaris Therapeutics Stock Forecast NASDAQ:ACRS

$12.62 (-5.82%)

Volume: 216k

Closed: Nov 26, 2021

Hollow Logo Score: -4.989

Aclaris Therapeutics Stock Forecast

$12.62 (-5.82%)

Volume: 216k

Closed: Nov 26, 2021

Score Hollow Logo -4.989
Which way will ACRS go? Request
Key Stats
P/E Ratio -9.51
Beta 1.85
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Aclaris Therapeutics stock currently holds an RSI14 at 22 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Very red day for Aclaris Therapeutics stock price after -5.82% fall in Friday trading session
(Updated on Nov 26, 2021)

Sell candidate since 2021-11-02 Loss -23.42%

The Aclaris Therapeutics stock price fell by -5.82% on the last day (Friday, 26th Nov 2021) from $13.40 to $12.62. During the day the stock fluctuated 6.77% from a day low at $12.40 to a day high of $13.24. The price has fallen in 8 of the last 10 days and is down by -17.25% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -29 thousand shares and in total, 216 thousand shares were bought and sold for approximately $2.73 million.

The stock has broken the wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($14.79) are considered to be a "second chance" to get out. According to the fan-theory $12.05 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

There are few to no technical positive signals at the moment. The Aclaris Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $13.35 and $15.78. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, November 01, 2021, and so far it has fallen -31.75%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.84 between high and low, or 6.77%. For the last week, the stock has had a daily average volatility of 7.02%.

Aclaris Therapeutics is oversold on RSI14 (22). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Aclaris Therapeutics stock A Buy?

Aclaris Therapeutics holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.989

Predicted Opening Price for Aclaris Therapeutics of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$12.75 $12.62 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 15, 2021 "HC Wainwright" gave "$49.00" rating for ACRS. The price target was changed from $14.90 to 0.1%.

Volatility and Risk
Daily Average Volatility: 7.02 %
Overall Risk: Very High High Medium Low Very Low
7.02 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $12.76
Price: $12.62
No Support Found

ACRS Insider Trading Show all Trades



Last 100 transactions
Buy: 848 700 | Sell: 2 834 424 (Shares)
Date Action Amount Person Type
Nov 01, 2021 Buy 8 276 Foresite Capital Management Iii, Llc Common Stock
Nov 01, 2021 Sell 1 954 904 Foresite Capital Management Iii, Llc Common Stock
Sep 01, 2021 Sell 1 041 Monahan Joseph Common Stock
Sep 01, 2021 Buy 2 333 Monahan Joseph Common Stock
Sep 01, 2021 Sell 2 333 Monahan Joseph Restricted Stock Units
Show all Insider Trades


Last 100 transactions
Buy: 848 700 | Sell: 2 834 424 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 13.59 7.71 %
13.27 5.17 %
13.07 3.60 %
Current price: 12.62
Support 12.43 -1.49 %
12.23 -3.06 %
11.91 -5.60 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 15.25 20.84 %
13.79 9.27 %
12.76 1.11 %
Current price 12.62
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription t... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE